EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer

Helena Oliveres, Marta Cascante, Joan Maurel

Current Opinion in Chemical Biology · 2023-12 · 77 · 102401

DOI: 10.1016/j.cbpa.2023.102401 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Opinion in Chemical Biology, 2023-12. Verfasst von Helena Oliveres und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Barcelona…. Hauptthemen laut MEDLINE: Colorectal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ISCIII, Fundacion Cientifica de la Asociacion Espaoola Contra el Cancer, ICREA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current standard-of-care for metastatic colorectal cancer patients includes chemotherapy and anti-angiogenic or anti-epidermal growth factor receptor for microsatellite stable tumors and pembrolizumab for microsatellite instable tumors. However, despite the available therapies, the prognosis remains poor. In recent years, new drugs combined with immune checkpoint inhibitors have been tested in microsatellite stable metastatic colorectal cancer patients, but the benefit was modest. Here, we review the metabolic interactions between the immune microenvironment and cancer cells. More specifically, we highlight potential correlatives of tumor immune and metabolic features with transcriptomic classifications such as the Consensus Molecular Subtype. Finally, we discuss the unmet need of immune-metabolic signatures and the value of a new signature (IMMETCOLS) for guiding new strategies in metastatic colorectal cancer. We conclude that the field is ready to propose customized strategies for modifying metabolism and improving immunotherapy and targeted therapy efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsHumansImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

ImmunotherapyMetabolismResistance

Autor:innen und Institutionen

  • Medical Oncology Department, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Biochemistry and Molecular Biomedicine and Institute of Bi…
  • Medical Oncology Department, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepá…

Förderung

  • ISCIII
  • Fundacion Cientifica de la Asociacion Espaoola Contra el Cancer
  • ICREA
  • Ministerio de Ciencia e Innovación
  • AGAUR
  • Fundación Olga Torres
  • Gobierno de España Ministerio de Ciencia e Innovación

Zitieren

APA

Oliveres, H., Cascante, M., & Maurel, J. (2023). Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer. Current Opinion in Chemical Biology, 77, 102401. https://doi.org/10.1016/j.cbpa.2023.102401

Vancouver

Oliveres H, Cascante M, Maurel J. Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer. Current Opinion in Chemical Biology. 2023;77:102401. doi:10.1016/j.cbpa.2023.102401

BibTeX
@article{Oliveres2023,
  author = {Oliveres, Helena and Cascante, Marta and Maurel, Joan},
  title = {Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer},
  journal = {Current Opinion in Chemical Biology},
  year = {2023},
  volume = {77},
  pages = {102401},
  doi = {10.1016/j.cbpa.2023.102401}
}
Kostenlos starten →